08.12.25 -- CDMOs Should Stop Stringing Biotechs Along

A cost-effective approach with a comprehensive AAV analytical package holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.

Explore advanced production platforms that enhance efficiency, scalability, and compliance, paving the way for safe and accessible gene therapies.

Ensure your cell therapy program is prepared for the future by learning how to effectively navigate sourcing, logistics, and manufacturing challenges with confidence.

Analytical assays aren't just important for quality control. Regulators expect them. These tips will help if you're just starting to build your analytical package.

Discover how one family defied the odds—bringing a lifesaving gene therapy from idea to treatment in just 14 months after a devastating rare disease diagnosis.

It is crucial to ensure that CGT supply chain risks are mitigated, as well as to have proactive strategies in place to address unforeseen challenges before they become an issue.

Witness as pharma leaders discuss advancing equity through inclusive trial design and global partnerships to overcome health disparities and expand access to lifesaving therapies worldwide.

Examine the escalating rigor from assessing feasibility in preclinical studies to fully validated release methods and lifecycle management in commercial supply.

By leveraging cells equipped with an existing TARGATT™ landing pad, we demonstrate how inducible expression can be efficiently achieved within just 4-6 weeks after donor plasmid creation.

Unlock the potential of AAV manufacturing by leveraging data-driven insights and the advanced Pro10™ platform to optimize processes, enhance productivity, and drive innovation in cell and gene therapy.

Gain insight on how this plasma-based measurement has the potential to serve as a critical pharmacodynamic biomarker, facilitating the assessment of novel therapeutic approaches.

Learn how this process development platform for MVA impacts vaccine manufacturing and supports the drug life cycle from process and analytical development through trials and commercialization.

Delve into how cloud-based systems and unified data platforms are transforming biomanufacturing by enhancing efficiency, ensuring quality, and accelerating the delivery of complex therapies to market.

Consider how an intensified adherent AAV manufacturing process is unlocking high-yield, low-impurity clinical production with over 95% full capsids in a streamlined, compact platform.

We offer comprehensive technology platforms and services to expedite the discovery, development, testing, manufacturing, and commercialization of clients' pipeline.

Translating mRNA sequences to a high-quality drug product presents a complex challenge. Observe how partnering with a single contract manufacturer can alleviate potential delays and risks.

In cell and gene therapies, your process is the product. Our team of experts develops, defines, and refines processes for maximum efficiency and scale.

As a CDMO Partner for Life, our goal is to advance your cell therapies from lab to commercial scale, leveraging our cell and gene therapy expertise and global cGMP network.